{"id":52535,"date":"2023-01-04T17:03:03","date_gmt":"2023-01-04T16:03:03","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/biological-dynamics-files-legal-action-against-co-founders-of-exokeryx\/"},"modified":"2023-01-04T17:03:03","modified_gmt":"2023-01-04T16:03:03","slug":"biological-dynamics-files-legal-action-against-co-founders-of-exokeryx","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/biological-dynamics-files-legal-action-against-co-founders-of-exokeryx\/","title":{"rendered":"Biological Dynamics Files Legal Action Against Co-founders of EXOK\u0112RYX"},"content":{"rendered":"
\n

\nArbitration filed against two former Biological Dynamics\u2019 employees, vice presidents of core technology research and manufacturing, to protect the company\u2019s proprietary exosome-isolation technology<\/i>\n<\/p>\n

<\/a><\/p>\n

SAN DIEGO–(BUSINESS WIRE)–Biological Dynamics today announced it has filed arbitration against two former employees, Richard Young and Bryan Rice, alleging that they have misappropriated Biological Dynamics\u2019 proprietary technology to benefit their new company, EXOK\u0112RYX, Inc. The Company believes that this new enterprise unfairly competes with Biological Dynamics\u2019 exosome-isolation ExoVerita\u2122 platform and its derivatives.\n<\/p>\n

\nBiological Dynamics has invested more than 10 years in innovative research and development to build its proprietary lab-on-a-chip platform, which detects cancer and other diseases using its unique and patent-protected technology. Biological Dynamics believes it has found evidence of misappropriation of its IP and know-how, and it is prepared to take all actions necessary to enforce its rights, protect its commercial interests, and ensure that all current and former employees adhere to their contractual obligations to the Company.\n<\/p>\n

\n\u201cAn important priority for Biological Dynamics is to rigorously protect our proprietary technologies and to advance our life-changing products and services. With mounting evidence against these former employees and their new company, we intend to take all necessary legal action to defend our intellectual property rights, while ensuring accountability and adherence to the contractual obligations,\u201d said Paul R. Billings, MD, PhD, CEO and Director of Biological Dynamics. \u201cWe are in an excellent position today, commencing commercialization, and fulfilling our mission to help improve care by providing early disease diagnosis for high-risk cancer patients,\u201d concluded Dr. Billings.\n<\/p>\n

\nBiological Dynamics\u2019 investigation of the alleged theft of proprietary technology and other confidential information by its former employees is ongoing and additional legal action may be necessary.\n<\/p>\n

\nAbout Biological Dynamics<\/b>\n<\/p>\n

\nBiological Dynamics, Inc. is committed to improving global health outcomes by detecting diseases at the earliest stages. The Company\u2019s proprietary ExoVerita\u2122 platform simplifies isolation of extracellular vesicles, enabling multiomic applications. In 2021, the U.S. Food and Drug Administration granted Breakthrough Device Designation<\/a> for its liquid biopsy assay for early detection of the aggressive and lethal pancreatic ductal adenocarcinoma in high-risk populations. Its AACC award-winning PDAC test<\/a> operates in a College of American Pathologists (CAP) accredited, CLIA-certified clinical laboratory in San Diego. It recently announced the initiation of the ExoLuminate\u2122study, a clinical trial to demonstrate effectiveness of early-stage detection of pancreatic cancer. Learn more at www.ExoLuminate.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nKellee Johnson for Biological Dynamics, 312-751-3959 or kjohnson@ballastgroup.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Arbitration filed against two former Biological Dynamics\u2019 employees, vice presidents of core technology research and manufacturing, to protect the company\u2019s proprietary exosome-isolation technology SAN DIEGO–(BUSINESS WIRE)–Biological Dynamics today announced it has filed arbitration against two former employees, Richard Young and Bryan Rice, alleging that they have misappropriated Biological Dynamics\u2019 proprietary technology to benefit their new … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-52535","6":"format-standard","7":"category-industry"},"yoast_head":"\nBiological Dynamics Files Legal Action Against Co-founders of EXOK\u0112RYX - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/biological-dynamics-files-legal-action-against-co-founders-of-exokeryx\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biological Dynamics Files Legal Action Against Co-founders of EXOK\u0112RYX - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Arbitration filed against two former Biological Dynamics\u2019 employees, vice presidents of core technology research and manufacturing, to protect the company\u2019s proprietary exosome-isolation technology SAN DIEGO–(BUSINESS WIRE)–Biological Dynamics today announced it has filed arbitration against two former employees, Richard Young and Bryan Rice, alleging that they have misappropriated Biological Dynamics\u2019 proprietary technology to benefit their new ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/biological-dynamics-files-legal-action-against-co-founders-of-exokeryx\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-04T16:03:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230104005639\/en\/1676649\/21\/static1.squarespace.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biological-dynamics-files-legal-action-against-co-founders-of-exokeryx\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biological-dynamics-files-legal-action-against-co-founders-of-exokeryx\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Biological Dynamics Files Legal Action Against Co-founders of EXOK\u0112RYX\",\"datePublished\":\"2023-01-04T16:03:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biological-dynamics-files-legal-action-against-co-founders-of-exokeryx\\\/\"},\"wordCount\":414,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biological-dynamics-files-legal-action-against-co-founders-of-exokeryx\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230104005639\\\/en\\\/1676649\\\/21\\\/static1.squarespace.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biological-dynamics-files-legal-action-against-co-founders-of-exokeryx\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biological-dynamics-files-legal-action-against-co-founders-of-exokeryx\\\/\",\"name\":\"Biological Dynamics Files Legal Action Against Co-founders of EXOK\u0112RYX - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biological-dynamics-files-legal-action-against-co-founders-of-exokeryx\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biological-dynamics-files-legal-action-against-co-founders-of-exokeryx\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230104005639\\\/en\\\/1676649\\\/21\\\/static1.squarespace.jpg\",\"datePublished\":\"2023-01-04T16:03:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biological-dynamics-files-legal-action-against-co-founders-of-exokeryx\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biological-dynamics-files-legal-action-against-co-founders-of-exokeryx\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biological-dynamics-files-legal-action-against-co-founders-of-exokeryx\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230104005639\\\/en\\\/1676649\\\/21\\\/static1.squarespace.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230104005639\\\/en\\\/1676649\\\/21\\\/static1.squarespace.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biological-dynamics-files-legal-action-against-co-founders-of-exokeryx\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biological Dynamics Files Legal Action Against Co-founders of EXOK\u0112RYX\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biological Dynamics Files Legal Action Against Co-founders of EXOK\u0112RYX - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/biological-dynamics-files-legal-action-against-co-founders-of-exokeryx\/","og_locale":"en_US","og_type":"article","og_title":"Biological Dynamics Files Legal Action Against Co-founders of EXOK\u0112RYX - Pharma Trend","og_description":"Arbitration filed against two former Biological Dynamics\u2019 employees, vice presidents of core technology research and manufacturing, to protect the company\u2019s proprietary exosome-isolation technology SAN DIEGO–(BUSINESS WIRE)–Biological Dynamics today announced it has filed arbitration against two former employees, Richard Young and Bryan Rice, alleging that they have misappropriated Biological Dynamics\u2019 proprietary technology to benefit their new ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/biological-dynamics-files-legal-action-against-co-founders-of-exokeryx\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-04T16:03:03+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230104005639\/en\/1676649\/21\/static1.squarespace.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/biological-dynamics-files-legal-action-against-co-founders-of-exokeryx\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/biological-dynamics-files-legal-action-against-co-founders-of-exokeryx\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Biological Dynamics Files Legal Action Against Co-founders of EXOK\u0112RYX","datePublished":"2023-01-04T16:03:03+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/biological-dynamics-files-legal-action-against-co-founders-of-exokeryx\/"},"wordCount":414,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/biological-dynamics-files-legal-action-against-co-founders-of-exokeryx\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230104005639\/en\/1676649\/21\/static1.squarespace.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/biological-dynamics-files-legal-action-against-co-founders-of-exokeryx\/","url":"https:\/\/pharma-trend.com\/en\/biological-dynamics-files-legal-action-against-co-founders-of-exokeryx\/","name":"Biological Dynamics Files Legal Action Against Co-founders of EXOK\u0112RYX - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/biological-dynamics-files-legal-action-against-co-founders-of-exokeryx\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/biological-dynamics-files-legal-action-against-co-founders-of-exokeryx\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230104005639\/en\/1676649\/21\/static1.squarespace.jpg","datePublished":"2023-01-04T16:03:03+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/biological-dynamics-files-legal-action-against-co-founders-of-exokeryx\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/biological-dynamics-files-legal-action-against-co-founders-of-exokeryx\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/biological-dynamics-files-legal-action-against-co-founders-of-exokeryx\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230104005639\/en\/1676649\/21\/static1.squarespace.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230104005639\/en\/1676649\/21\/static1.squarespace.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/biological-dynamics-files-legal-action-against-co-founders-of-exokeryx\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Biological Dynamics Files Legal Action Against Co-founders of EXOK\u0112RYX"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52535","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=52535"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52535\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=52535"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=52535"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=52535"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}